Solubility enhancement of biperidine HCl by complexation with hydroxypropyl β-cyclodextrin
Keywords:β-Cyclodextrin, Biperiden HCl, Parkinson’s disease
Oral route is the simplest and easiest way of drug administration, because of the greater stability, lesser bulk, and cheap cost of production, accurate dosage and easy process, solid oral dosage forms have several advantages over other dosage forms. All the poor water soluble drugs after oral administrations are not well absorbed and thus leads to decrease in inherent efficiency of drugs. Therefore, for oral drug delivery system the improvement of drug solubility thereby its oral bio-availability is the most important aspect of drug development process. Biperiden HCl is a potent drug (Maximum daily dose is 16mg/day), having extensive first pass metabolism resulting in poor Bioavailability. The pharmacokinetic profile of this drug showed 33±5 % Bioavailability and 18-24 hours elimination half-life (t1/2). In the present study attempt has been made to prepare and characterize inclusion complex of Biperiden HCl with Hydroxypropyl β-Cyclodextrin. The inclusion complexes prepared by different methods i.e. Physical mixture, Kneading and Solvent evaporation methods. The prepared complexes were characterized using FT-IR. The inclusion complex prepared by Kneading method exhibited greatest enhancing in solubility and faster dissolution (93.98% drug release in 60 min) of Biperiden HCl.
Patil J S, Kadam D V, Marapur S C, et al. Inclusion complex system; A novel technique to improve the solubility and bioavailability of poorly soluble drugs: A Review. Int. J. Pharm. Sci. Vol.2, 2010, 29-34.
Loftsson Thorsteinn, Marcus E Brewster. Pharmaceutical applications of cyclodextrins. Journal of Pharmaceutical Sciences, 85(10), 1996, 1017-1026.
Marcus E Brewstera, Thorsteinn Loftsson. Cyclodextrin as pharmaceutical solubilizers. Adv. Drug Delivery Reviews. 59, 2007, 645-666.
K.P.R. Chowdary and G Kamalakara Reddy. Complexes of Nifedipine with β- and hydroxypropyl β-cyclodextrins in the design of Nifedipine SR tablets. Ind. J. of Pharm. Sci., Mar-Apr. 2002: 142-146.
Sanoferjan AM, Nanjundaswamy NG. Mahesh S and Narasimhamurty S. Formulation and evaluation of β-cyclodextrin complexes of tenoxicam. Ind. J. of Pharm. Sci., March 2000; 62(2): 119-121.
Loftsson T, Masson M, Brewster ME, Selfassociation of cyclodextrins and cyclodextrin complexes, J Pharm Sci, 93(5), 2004, 2307-2316.
Mallwswara Rao P.et al. Int. J. of Research in Pharm. and Nano Sciences 2(6),2013,757-767.
How to Cite
Copyright (c) 2020 Amit Dubey, Vikram Singh, Divya Juyal, Geeta Rawat
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In submitting an article to Journal of Applied Pharmaceutical Research (JOAPR) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JOAPR are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in Journal of Applied Pharmaceutical Research (JOAPR) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.